|
|
|
Sunday, March 21, 2010 — 1:30 PM, Salon 2
|
- Pathogenesis and Diagnosis of Plasma Cell Neoplasms
|
|
Moderators:
|
Robert B. Lorsbach, University of Arkansas for Medical Sciences, Little Rock, AR and
Robert W. McKenna, University of Minnesota, Minneapolis, MN
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. The speakers listed below have indicated they have nothing to disclose.
|
Click the button above to add this event to your Itinerary Planner...
| 1:30 | Introduction - Robert B. Lorsbach, University of Arkansas for Medical Sciences, Little Rock, AR |
| 1:40 | Genetic Events in the Pathogenesis of Plasma Cell Myeloma - Michael Kuehl, Center for Cancer Research, NCI, NIH, Bethesda Naval Hospital, Bethesda, MD |
| 2:20 | Molecular Classification of Plasma Cell Myeloma - John Shaughnessy, University of Arkansas for Medical Sciences, Little Rock, AR |
| 3:00 | Break |
| 3:30 | Role of Flow Cytometry in Myeloma, New Diagnosis and MRD - Steven H. Kroft, Medical College of Wisconsin, Milwaukee, WI |
| 4:00 | What's New for the Treatment of Multiple Myeloma and Related Disorders in 2010? - Angela Dispenzieri, Mayo Clinic, Rochester, MN |
| 4:30 | Panel Discussion - All Presenters and Moderators with Audience Participation |
The Executive Committee of the Society for Hematopathology determines the subjects for symposia based on input from the membership of the Society.
The topic was chosen from a survey of members conducted by the Society for Hematopathology which identified plasma cell myeloma as a topic that they were highly interested in for a future symposium.
Rapid advances in understanding the pathogenesis of plasma cell myeloma have occurred in recent years accompanied by significant advances in treatment of patients with myeloma. In addition, an updated WHO classification of plasma cell neoplasms was included as part of the WHO "Classification of Tumours of Haematopoietic and Lymphoid Tissues" in 2008. Thus, there is a need to update Society members and the hematopathology community at large.
The purpose of the program will be to provide members of the Society and others with an interest in hematopathology an in-depth discussion of recent advances in the molecular pathogenesis and classification of plasma cell myeloma, the role of flow cytometry in diagnosis and disease monitoring, and recent advances in the treatment of plasma cell myeloma. |
|
|
|
